Granules India Limited Honoured with Golden Peacock Award for Sustainability, Setting New Standards in Environmental Responsibility
Mr. Ovais Sarmad joins as Advisor to Granules India Limited to Guide Sustainability and Climate Strategy
Granules India’s Unit V Facility Secures US FDA EIR with ‘No Action Indicated’ Status
Quarterly Results- FY25-Q2
Granules India Limited Announces ANDA Approval for Bupropion Hydrochloride Extended-Release Tablets
Granules India Unveils ‘Breast Health Express’ Mobile Unit: A Leap in Cancer Screening for Underserved Communities
Granules India’s Gagillapur Facility Completes US FDA Inspection with Six Observations
Granules India Limited Receives ANDA Approval for Glycopyrrolate Oral Solution
Granules India Limited Announces ANDA Approval for Trazodone Tablets
Quarterly Results- FY25-Q1
Annual Financial Results – FY24
ANDA Approval for Colchicine Capsules 0.6 mg
Quarterly Results-FY24-Q3
Granules India Limited Received ANDA approval for Pantoprazole Sodium Delayed-Release Tablets
Granules India Limited received ANDA approval for Sildenafil for Oral Suspension
Quarterly Results-FY24-Q2
Granules India Limited Received ANDA Approval for Esomeprazole Magnesium Delayed-Release Capsules
Granules India Limited Received ANDA Approval for Losartan and Hydrochlorothiazide Tablets
Quarterly Results -FY24- Q1
Granules Pharmaceuticals, Inc. Successfully Completes USFDA Post-marketing Adverse Drug Experience (PADE) Inspection with Zero Observations
Granules India Limited announces US FDA approval OTC (Store brand) equivalent of Advil® Dual Action Tablets.
Granules India and Central Bureau of Narcotics Unite to Tackle Drug Abuse on International Day against Drug Abuse and Illicit Trafficking
Successfully Completes Two US FDA Audits in a Span of Two Weeks for its Vizag and Jeedimetla facilities with Zero Observations
Granules India Limited Receives ANDA Approval for Levetiracetam Tablets in record 9 months
Granules India Limited Received ANDA Approval for Metoprolol Succinate ER Tablets
Granules India Limited Received ANDA Approval for Venlafaxine ER Capsules
Quarterly Results-FY23-Fourth Quarter
Losartan Tabs Press Release (002)
Granules India Limited Received ANDA Approval for Gabapentin Tablets
Granules Consumer Health Inc., inaugurates its Packaging Facility in the U.S.
GCH concluded U S FDA audit
Granules India Limited Received ANDA Approval for Losartan Potassium Tablets
Quarterly Results -FY23-Third Quarter
Granules Pharmaceuticals Inc., Receives ANDA Approval for Amphetamine Mixed Salts ER Capsules
Press Note – Granules Enters into a Strategic Partnership With Greenko ZeroC To Enable Carbon Free Energy and Green Molecule Solutions
Quarterly Results- FY23- Second Quarter
Press Release – Granules India Limited Inaugurated an Overhead Water Tank at Bonthapally
Granules India Limited Received ANDA Approval for Loperamide Hydrochloride and Simethicone Tablets
Granules India Limited Received ANDA Approval for Guaifenesin and Pseudoephedrine Hydrochloride Extended-Release Tablets
Quarterly Results -FY23-First quarter
Granules Quarterly Results -FY22 -Fourth Quarter
Granules India Receives Licences from MPP to Market Nirmatrelvir; Ritonavir
Granules Pharmaceuticals Inc., Clears US FDA Audit
Press Release on Q3 Financials of FY22
Granules Pharmaceuticals Inc., Receives ANDA Approval for Bupropion Hydrochloride Extended-Release Tablets
Granules Pharmaceuticals Inc., concludes US FDA Audit with Three Minor Observations
Press Note – Granules Pharmaceuticals Inc., Receives ANDA Approval for Potassium Chloride for Oral Solution USP, 20 mEq
Granules India appoints Dr. K.V.S Ram Rao as Joint Managing Director and Chief Executive Officer.
Granules India appoints Sucharita Rao Palepu as Non-executive Independent Director
Granules Pharmaceuticals Inc., Receives ANDA Approval for Amphetamine Mixed Salts (IR Tablets)
Granules Pharmaceuticals, Inc. receives ANDA approval for Prazosin Hydrochloride Capsules
Granules India appoints Dr. Saumen Chakraborty as Non-executive Independent Director
Press Release on Q2 financials for FY22
Voluntary recall of one batch of Naproxen Sodium 220mg tablets
Granules India Limited Received Approval from the Health Canada for Acetaminophen Extended-Release Tablets
Press Release on Q1 financials for FY22
Granules Pharmaceuticals, Inc. Clears US FDA Audit
FY21 Income from operations show a record growth – up 25% YoY
Granules India Limited announces approval of Acetaminophen, Aspirin and Caffeine Tablets (OTC), generic equivalent of Excedrin Migraine Tablets of GlaxoSmithKline Consumer Healthcare
Granules India Limited announces approval of Potassium Chloride ER Capsules USP, generic equivalent of Micro-K ER Capsules of Nesher Pharmaceuticals (USA) LLC
Granules Receives USFDA approval for Potassium Chloride Oral Solution USP
Granules Receives USFDA approval for Metformin Hydrochloride ER Tablets USP, 500 mg and 1000 mg.
ANDA approval for Penicillamine Capsules, 250 mg.
Granules India receives US FDA approval for Potassium Chloride Extended Release Tablets USP, 10 mEq (750 mg) and 20 mEq (1500 mg)
Granules receives US FDA approval of Naproxen Sodium and Diphenhydramine Hydrochloride Tablets, 220 mg/25 mg (OTC)
Granules Receives USFDA approval for complex, Attention Deficit Hyperactivity Disorder (ADHD) Drug
Granules Pharmaceuticals, Inc. issues clarification on media reports
Granules Pharmaceuticals, Inc. issues Voluntary Nationwide Recall of Metformin Hydrochloride Extended-Release Tablets USP, 750 mg
Release of Pledge on Company’s Shares
ANDA approval for Vigabatrin for Oral Solution USP, 500 mg
ANDA approval for Trospium Chloride ER Capsules, 60 mg
ANDA approval for Butalbital, Acetaminophen and Caffeine Capsules USP
USFDA completes inspection at Granules India’s Hyderabad facility
ANDA approval for Guaifenesin Extended-Release Tablets
ANDA approval for Colchicine Capsules
ANDA approval for Colchicine Tablets
Granules India’s Q2FY20 Adjusted Net Profit up 103%
Granules India Limited to divest its stake in its Joint Venture located in China
Granules India Limited to divest its stake in its Joint Venture located in India
Granules India’s Net Profit for first quarter of Financial Year 2020 increases by 61%
Granules India’s Total Income of FY’19 increases by 35% to INR 2,306 Cr. with Net Profit growth by 78% to INR 236 Crs.
ANDA approval for Acetaminophen 650 mg, Extended Release Tablets.
Promoters Block deal.
Granules India’s Net Profit grew by 72% to INR 60 Cr.
Granules India’s Net Profit grew by 49% to INR 60 Cr
Granules India’s Total Income increases by 21% to INR 468 Cr.
Granules Pharmaceuticals, Inc. launched the generic version of Methylergonovine Maleate Tablets, USP, 0.2mg
Granules India’s Total Income increases by 18% to INR 1,703 Cr
Granules Pharmaceuticals, Inc. received US FDA approval for generic Methylergonovine tablets
Granules India’s Revenue from operation increases by 14% to INR 411 Cr.
Granules India’s Revenue from operation increases by 8% to INR 393 Cr.
Details Granules India’s Revenue increases by 10% to Rs. 386 Cr.
Granules India’s Revenue increases 4% to Rs. 1,435 Cr.; Net Profit surges 34% to Rs. 165 Cr.
Granules India’s Net Profit rises by 34% to Rs. 39 Cr.
Granules India’s clarification on market rumours brought to our notice by few shareholders
Granules Pharmaceuticals, Inc., wholly owned subsidiary of Granules India Ltd entered into an agreement with USpharma to acquire its stake
Granules Pharmaceuticals, Inc., wholly owned subsidiary of Granules India Ltd entered into an agreement with USpharma Windlas, LLC for product in-licensing
Granules India’s Jeedimetla plant received Establishment Inspection Report (EIR) from the US FDA
Granules India’s Revenue increases 11% to Rs. 1,431 Cr.; Net Profit surges 30% to Rs. 118 Cr.
Granules India’s Revenue increases 8% to Rs. 345 Cr.; Net Profit surges 15% to Rs. 27 Cr
Granules USA entered into an agreement with Par Pharmaceutical Inc. to market generic version of omeprazole and sodium bicarbonate
Granules India’s two facilities located in Vizag and Jeedimetla completed U.S. FDA inspection
Granules India’s Revenue increases 19% to Rs. 366 Cr.; Net Profit surges 40% to Rs. 31 Cr.
Granules India receives US FDA approval for Ibuprofen Tablets
Granules India’s Revenue increases 11% to Rs. 346 Cr.; Net Profit surges 19% to Rs. 27 Cr.
Granules India’s FY15 Revenue increases 18% to Rs. 1,293 Cr.; Net Profit rises 21% to Rs. 91 Cr
Granules-OmniChem Private Ltd., inaugurated manufacturing facility today in Vizag
Granules India’s Revenue increases 13% to Rs. 320 Cr.; net profit increased Rs. 24 Cr
Details Hon’ble High Court of Hyderabad approved the merger of Auctus Pharma with Granules India
Granules India’s Revenue increases 16% to Rs. 308 Cr.; net profit surges 46% to Rs. 22 Cr
Granules India´s Revenue increases 36% to Rs. 311 Cr.; net profit surges 56%
Granules India Paracetamol API Facility completes U.S. FDA Inspection
Granules India Awarded Outstanding Exports (Europe & CIS) Gold Award 2012-13 by Pharmexcil
Demise of Founder and Chairman
Granules India FY14 Sales increase 43% to Rs. 1,096 Cr.; Net Profit jumps 131% to Rs. 75 Cr
Granules India sales increases 46% to Rs. 284 Cr.; net profit surges 275% to Rs. 22 Cr.
Granules India announces acquisition of Auctus Pharma and opening of a new R&D Facility
Granules India Revenue increases 52% to Rs. 266 Cr.; net profit surges 87%
Granules India Revenue increases 21% to Rs. 228 Cr.; net profit surges 134%
Granules India’s FY13 Sales increases 17% to Rs.764cr.; Net Profit increases 9% to Rs.33cr.
Granules India’s sales set quarterly record at Rs.195cr.
Granules India’s revenue increases to Rs.176cr.; net profit incresed by 228%.
Granules India Awarded Outstanding Exports – Formulations Award 2011-12 by Pharmexcil.
Granules India Awarded India’s Most Admired Company in Exports & India’s Most Admired Company in Bulk Drugs
Granules India Net Revenue increases 9% due to strong …
Granules India Sales increases 59% to Rs. 189 Cr. Net…
Granules India Announces Dividend Increase of 33% second…
Granules India Announces New Chief Financial Officer
Granules India FY12 Revenue increases 37% to Rs. 653 …
Granules India Sales increases 45% to Rs. 186 Cr. Net …
Granules India Net Revenue soars 37%; PBT before non-…
Granules India Receives U.S. FDA Approval for its Naprox…
Granules India Net Profit excluding exceptional items…
Granules India Announces New Leadership Roles
Granules India Posts Revenue of Rs.109.3 Cr. for Q1 FY11…
Granules India and Ajinomoto OmniChem to create a strate…
Granules India Posts Strong Growth During FY10 Net Revenue
Granules India Post s Record Revenue for a Quarter – Net R…
